Trade group gives its take on EU pharma legislation reform

Medicines for Europe has said that it sees the revision of European Union (EU) pharmaceutical legislation as an opportunity to accelerate patient access to safe, effective, and affordable medicines and to improve security of supply.

The EU’s major overhaul of its pharma legislation covers areas ranging from regulation to intellectual property and supply chains.

According to Medicines for Europe, the trade group representing generics and biosimilar firms, the off-patent medicines industry is fully engaged to ensure that reforms transform healthcare delivery and access for patients.